公开(公告)号：US20220324970A1

公开(公告)日：2022-10-13

申请号：US17630718

申请日：2020-07-31

Applicant: JANSSEN BIOTECH, INC.

Inventor： Rajkumar GANESAN ,  Bharathikumar Vellalore MARUTHACHALAM ,  Adam ZWOLAK ,  Brian GEIST ,  Xiefan LIN-SCHMIDT ,  Sathyadevi VENKATARAMANI ,  Sanjaya SINGH

IPC: C07K16/28 ,  A61K47/68 ,  A61K47/65

Abstract: A method is described for delivering a single domain antibody or a therapeutic molecule from an apical surface of a polymeric immunoglobulin receptor (pIgR)-expressing cell to a basolateral surface of the pIgR-expressing cell comprising contacting the pIgR-expressing cell with the single domain antibody or the therapeutic molecule, wherein the single domain antibody binds to pIgR, and the therapeutic molecule comprises an agent and the single domain antibody. A method is also described for transporting such a therapeutic molecule to systemic circulation or lamina propria or gastrointestinal tract of a subject comprising administering the therapeutic molecule to the subject via oral delivery, buccal delivery, nasal delivery or inhalation delivery.

公开(公告)号：US20250011454A1

公开(公告)日：2025-01-09

申请号：US18703264

申请日：2022-10-19

Applicant: Janssen Biotech, Inc.

Inventor： Adam ZWOLAK ,  Jason HO ,  James TESTA, Jr. ,  Michael Riis HANSEN ,  Xiefan LIN-SCHMIDT ,  Ian WHITE ,  Sanjaya SINGH

IPC: C07K16/28 ,  C07K16/30

Abstract: Provided herein, in certain aspects, is a binding molecule comprising an antigen binding domain and an Fc region; wherein the antigen binding domain is monovalent and the Fc region comprises K248E and T437R mutations (RE mutations), wherein amino acid residue numbering is according to the EU numbering system; wherein the binding molecule has increased capability of hexamerization on a cell surface, and/or increased capability of engaging C1q.

公开(公告)号：US20230019640A1

公开(公告)日：2023-01-19

申请号：US17630706

申请日：2020-07-31

Applicant: JANSSEN BIOTECH, INC.

Inventor： Rajkumar GANESAN ,  Bharathikumar Vellalore MARUTHACHALAM ,  Adam ZWOLAK ,  Brian GEIST ,  Xiefan LIN-SCHMIDT ,  Sathyadevi VENKATARAMANI ,  Sanjaya SINGH

IPC: C07K16/28 ,  A61K47/68 ,  A61P11/00

Abstract: VHH domains that bind to p1gR are described. The VHH domain may compete with IgA binding to p1gR, or alternatively, the VHH domain may compete with IgA binding to p1gR. The VHH domains may be coupled to therapeutic agents so as to facilitate delivery of the therapeutic agent to the mucosal layer via p1gR-mediated transcytosis. The therapeutic agent can be a small molecule, large molecule, or even an antibody.